The 40% increase in hospital doses and market share for Yupelri is driven by formulary approvals and therapeutic interchange protocols. Efforts to expand these strategies aim to sustain growth. A strategic review committee seeks to unlock value for shareholders, with ASP improvements expected in early 2025.